BAC free glaucoma therapy welcomed in Japan

The Ministry of Health, Labour and Welfare in Japan has approved Alcon's treatment for glaucoma and ocular hypertension, TRAVATANZ 0.004%.

The Ministry of Health, Labour and Welfare in Japan has approved Alcon's treatment for glaucoma and ocular hypertension, TRAVATANZ 0.004%.

TRAVATANZ is the first prostaglandin analogue that does not contain benzalkonium chloride (BAC), a preservative that is commonly used in topical ocular medications. Recent research has suggested that BAC could negatively affect the ocular surface. To this end, Alcon developed TRAVATANZ as a BAC free version of it glaucoma therapy, TRAVATAN.

TRAVATANZ was approved as TRAVATAN Z in the US in 2006.

Related Videos
Disrupting the glaucoma treatment paradigm with novel femtosecond laser from ViaLase
2-year data in contralateral eye evaluation gives edge to iStent inject over Hydrus stent
Should endocyclophotocoagulation be considered part of MIGS? Mr Ratnarajan delves in
Investigating the effects of canaloplasty on corneal epithelium
Related Content
© 2023 MJH Life Sciences

All rights reserved.